Supplementary information for the manuscript:

Sulindac Sulfide Induces the Formation of Large Oligomeric Aggregates of the Alzheimer's Disease Amyloid-β Peptide Which Exhibit Reduced Neurotoxicity

Authors:

Elke Prade¹, Dr. Christian Barucker², Dr. Riddhiman Sarkar¹, Dr. Gerhard Althoff-Ospelt³, Dr. Juan Miguel Lopez del Amo⁴, Shireen Hossain², Yifei Zhong², Prof. Dr. Gerd Multhaup², Prof. Dr. Bernd Reif^{*1,5}

Affiliations:

¹ Munich Center for Integrated Protein Science (CIPS-M) at Department Chemie, Technische Universität München (TUM), Lichtenbergstr. 4, 85747 Garching, Germany.

² Department of Pharmacology & Therapeutics, McGill University, 3655 Promenade Sir-William-Osler, Montreal QC, H3G 1Y6, Canada.

³ Bruker BioSpin, Silberstreifen 4, 76287 Rheinstetten, Germany.

⁴ Current address: CIC Energigune, Albert Einstein 48, 01510 Miñano, (Álava), Spain.


⁵ Helmholtz-Zentrum München (HMGU), Deutsches Forschungszentrum für Gesundheit und Umwelt, Ingolstädter Landtstr. 1, 85764 Neuherberg, Germany.

* Email: reif@tum.de

Table of Contents


Results	3
Supplementary Figure 1: Solution-state NMR of A β and NSAIDs	3
Supplementary Figure 2: Analysis of solution-state NMR of A β and NSAIDs.	4
Supplementary Figure 3: Solution-state NMR studies of A β sidechains and NSAIDs	5
Supplementary Figure 4: Solid-state NMR spectra of NSAID induced A β aggregates	6
Supplementary Figure 5: 13 C- 19 F TEDOR spectra of NSAID induced A β aggregates	7
Supplementary Figure 6: Solid-state NMR pulse sequences	8
Supplementary Figure 7: Comparison of $^{13}C-^{19}F$ dipolar contacts between sulindac sulfide and A β fibrils or induced A β aggregates	
Supplementary Table 1: Chemical shifts assigned for Aβ aggregates induced by a 10-fold molar excess of sulindac sulfide	
References	1

Results




Supplementary Figure 1: Solution-state NMR of A β and NSAIDs. (A) ¹H-1D NMR spectra of monomeric A β in the presence of increasing concentrations of sulindac sulfide (left) and sulindac sulfone (right), as well as ¹H-¹⁵N HSQC of A β in the absence (black) and presence (red) of a 6-fold molar excess of sulindac sulfide (left) and


sulindac sulfone (right). Loss of signal intensities are observed with increasing concentrations of the NSAID, indicating aggregation of A β . (B) ¹H-1D NMR spectra of characteristic signals of sulindac sulfide (left) and sulindac sulfone (right) in the presence of a 50 μ M monomeric A β solution. Signal intensities are attenuated and broadened at a 4-fold molar excess of sulindac sulfide (blue) compared to lower concentrations (orange), whereas NMR signals of sulindac sulfone show an increase in peak intensity corresponding to the increase in NSAID concentration.




Supplementary Figure 2: Analysis of solution-state NMR of A β and NSAIDs. (A) CSPs $\Delta\delta$ (ppm) observed for A β in the presence of 5-fold molar excesses of sulindac sulindac sulfide (red) and sulindac sulfone (black) compared to monomeric A β . (B) Relative volumes of A β incubated in the presence of increasing amounts of sulindac sulfide extracted from ¹H-¹⁵N HSQC signals.



Supplementary Figure 3: Solution-state NMR studies of A β sidechains and NSAIDs. (A) ¹H-¹³C HSQC of A β in the presence of a 5-fold molar excess of sulindac sulfide (red) and 1% DMSO as a control (black). (B) relative volumes of ¹H-¹³C A β cross-peaks in the presence of a 5-fold molar excess of sulindac sulfide.




Supplementary Figure 4: Solid-state NMR spectra of NSAID induced A β aggregates. ¹³C-¹³C PDSD correlation spectrum of A β aggregated in the presence of a 5-fold (green) and 10-fold (red) molar excess of sulindac sulfide and 1% DMSO after 1 day, as well as A β in the presence of only 1% DMSO (black) as a control. NCACX and NCOCX experiments allowed sequential assignment of chemical shifts of individual resonances for residues E22-G38 for A β incubated in the presence of a 10-fold molar excess of sulindac sulfide (red). Squares indicated 1-3 are magnified in Fig. 3A.




Supplementary Figure 5: ¹³C-¹⁹F TEDOR spectra of NSAID induced A β aggregates. ¹³C-¹⁹F TEDOR spectra to detect dipolar contacts between ¹³C and ¹⁹F atoms in A β aggregates induced by sulindac sulfide (red), and for pure sulindac sulfide (black), respectively. The experiments were run with mixing times of 0.65, 1.29, 2.58, 5.16 and 7.74 ms. The sulindac sulfide spectra were subtracted from the spectrum obtained for A β aggregates with a

factor 0.5 to yield the difference spectra (green). In the lowest row, the HC CP ¹³C-1D experiments which show all ¹³C atoms in A β aggregates (gray) and pure sulindac sulfide (black) is represented. Vertical connecting lines are drawn to the full ¹³C spectra to guide the eye.



Supplementary Figure 6: Solid-state NMR pulse sequences. (A) ¹³C-¹⁵N TEDOR pulse sequence used to detect ¹³C atoms near the ¹⁹F- atom of sulindac sulfide. The pulse sequences are based on the 3D TEDOR experiments described by Jaroniec *et al.*¹ Black rectangles represent π/2-pulses and white rectangles represent π-pulses. Both experiment start with a ¹H-¹³C CP transfer. The TEDOR sequences consists of two REDOR periods, which allow to transfer magnetization from ¹³C to S spins, followed by an evolution period t₁. The experiment to detect the salt bridge was recorded in 2D-mode; the experiment to identify ¹⁹F nuclei near ¹³C atoms was recorded in 1D-mode. The following phase-cycles were used: (A) $\phi_1 = y, -y; \phi_2 = y; \phi_3 = x, x, -x, -x; \phi_4 = -x; \phi_5 = y, y, y, -y, -y, -y, -y; \phi_{rec} = x, -x, -x, x, x, x, x, x, x, +x; the REDOR π-pulses on ¹⁵N are phase-cycled employing the xy-16 scheme.² (B) <math>\phi_1 = y, -y; \phi_2 = y; \phi_3 = x, x, -x, -x, y, -y, -y, y, y, -y, -y, -y, -y, -y;$ The REDOR π-pulses on the ¹⁹F-spins are phase-cycled eomploying the xy-16 scheme. The phases for all other pulses were set to x.



Supplementary Figure 7: Comparison of ¹³C-¹⁹F dipolar contacts between sulindac sulfide and A β fibrils or induced A β aggregates. Black: ¹³C-¹⁹F TEDOR spectrum for a sample in which sulindac sulfide was titrated to monomeric A β using a 10-fold molar excess of sulindac sulfide. The TEDOR mixing time was set to of 2.58 ms. Red: ¹³C-¹⁹F REDOR spectrum for a sample in which a 5-fold molar excess of sulindac sulfide was titrated to preformed A β fibrils.³ In this experiment, the mixing time was set to 4.4 ms.

aa	N	со	Cα	Сβ	Сү	Сδ	Cε	Νζ	
V18	-	171.83	58.27	32.25	18.73	-	-		
F19	131.00	170.35	53.33	41.27		128.84			
F20	128.77	169.74	54.15	38.62		129.96	128.25		
A21	127.50	173.07	47.75	19.12	-	-	-		
E22	126.69	171.44	51.49	29.63	34.51	181.30	-		
D23	121.89	171.38	52.84	39.06	178.56	-	-		
V24	120.97	174.46	57.97	31.62	18.29	-	-		
G25	115.63	169.25	44.75	-	-	-	-		
S26	108.56	171.97	54.47	63.10	-	-	-		
N27	125.26	170.33	52.03	35.14	179.51	-	-		
K28	131.22	171.59	52.85	31.18	24.94	27.84	39.32	36.8	
G29	115.15	169.36	42.21	-	-	-	-		
A30	130.05	173.15	47.60	19.82	-	-			
131	127.18	171.42	58.40	38.77	15.43	11.76		_	
					26.08				
132	129.06	129.06	174.46	55.99	39.61	15.52	11.74		-
					25.34				
G33	121.73	169.49	45.97	-	-	-			
L34	120.88	120.88	171.84	50.72	43.91	25.15	23.05		-
						22.46			
M35	122.16	172.32	50.79	-	31.26	-	18.47		
V36	-	174.88	57.66	32.13	18.16	-	-		
G37	111.25	171.63	42.28	-	-	-	-		
G38	112.67	169.52	41.94	-	-	-	-		

Supplementary Table 1: Chemical shifts assigned for Aβ aggregates induced by a 10-fold molar excess of sulindac sulfide.

References

- [1] Jaroniec, C. P., Filip, C., and Griffin, R. G. (2002) 3D TEDOR NMR experiments for the simultaneous measurement of multiple carbon-nitrogen distances in uniformly (13)C,(15)N-labeled solids, *J. Am. Chem. Soc.* 124, 10728-10742.
- [2] Gullion, T., Baker, D. B., and Conradi, M. S. (1990) New, compensated Carr-Purcell sequences, J. Magn. Reson. 89, 479-484.
- [3] Prade, E., Bittner, H. J., Sarkar, R., Lopez Del Amo, J. M., Althoff-Ospelt, G., Multhaup, G., Hildebrand, P. W., and Reif, B. (2015) Structural Mechanism of the Interaction of Alzheimer Disease Abeta Fibrils with the Non-steroidal Anti-inflammatory Drug (NSAID) Sulindac Sulfide, J. Biol. Chem. 290, 28737-28745.